Chronic 1,4-butanediol treatment in rats: Cross-tolerance to γ-hydroxybutyrate and (±)-baclofen

European Journal of Pharmacology

Volumn 484, Issue 2-3, 2004, Pages 259-262

  Eckermann, Kary A ^a   Koek, Wouter ^a   France, Charles P ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

( ) Baclofen; 1,4 Butanediol; Cross tolerance; GABAB receptor; GHB ( hydroxybutyrate)

Indexed keywords

1,4 BUTANEDIOL; 4 HYDROXYBUTYRIC ACID; BACLOFEN;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG CROSS TOLERANCE; DRUG EFFECT; DRUG SENSITIVITY; DRUG WITHDRAWAL; GABAERGIC SYSTEM; LONG TERM CARE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; TREATMENT OUTCOME;

EID: 1642505607     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2003.11.016     Document Type: Article

References (21)

1. Bania T.C., Ashar T., Press G., Carey P.M. Gamma-hydroxybutyric acid tolerance and withdrawal in a rat model. Acad. Emerg. Med. 10:2003;697-704.
2. Barker S.A., Snead O.C., Poldrugo F., Liu C.C., Fish F.P., Settine R.L. Identification and quantitation of 1,4 butanediol in mammalian tissues: an alternative biosynthetic pathway for γ-hydroxybutyric acid. Biochem. Pharmacol. 34:1985;1849-1852.
3. Benavides J., Rumigny J.F., Bourguignon J.J., Cash C., Wermuth C.G., Mandel P., Vincenden G., Maitre M. High affinity binding sites for γ-hydroxybutyric acid in rat brain. Life Sci. 30:1982;953-961.
4. B receptors. Trends Pharmacol. Sci. 14:1993;259-261.
5. B receptors via its conversion into γ-hydroxybutyric acid. Eur. J. Pharmacol. 441:2002;157-163.
6. B receptors in the discriminative stimulus effects of γ-hydroxybutyrate in rats: time course and antagonism studies. J. Pharmacol. Exp. Ther. 305:2003;668-674.
7. Chabal C., Jacobson L., Terman G. Intrathecal fentanyl alleviates spasticity in the presence of tolerance to intrathecal baclofen. Anesthesiology. 76:1992;312-314.
8. Dyer J., Galbo M., Andrews K. 1,4 Butanediol "pine needle oil": overdose mimics toxic profile of GHB. J. Toxicol., Clin. Toxicol. 35:1997;554.
9. Galloway G.P., Frederick S.L., Staggers F. Physical dependence on sodium oxybate. Lancet. 343:1994;57.
10. Gianutsos G., Moore K.E. Tolerance to the effects of baclofen and γ-butyrolactone on locomotor activity and dopaminergic neurons in the mouse. J. Pharmacol. Exp. Ther. 207:1978;859-869.
11. Itzhak Y., Ali S.F. Repeated administration of gamma-hydroxybutyric acid (GHB) to mice: assessment of the sedative and rewarding effects of GHB. Ann. N.Y. Acad. Sci. 965:2002;451-460.
12. Nicholson K.L., Balster R.L. GHB: a new and novel drug of abuse. Drug Alchol Depend. 63:2001;1-22.
13. B-receptor antagonist, CGP 35348, antagonises γ-hydroxybutyrate- and baclofen-induced alterations in locomotor activity and forebrain dopamine levels in mice. J. Neural Transm. 103:1996;56-63.
14. B receptors: from pharmacology to molecular biology. Acta Pharmacol. Sin. 21:2000;111-123.
15. Roth R.H., Giarman N.J. Evidence that central nervous system depression by 1,4 butanediol is mediated through a metabolite, γ-hydroxybutyrate. Biochem. Pharmacol. 17:1968;735-739.
16. Schneir A.B., Ly B.T., Clark R.F. A case of withdrawal from the GHB precursors γ-butyrolactone and 1,4-butanediol. J. Emerg. Med. 21:2001;31-33.
17. Snead O.C. III, Liu C.C. γ-hydroxybutyric acid binding sites in rat and human brain synaptosomal membranes. Biochem. Pharmacol. 33:1984;2587-2590.
18. Snead O.C., Furner R., Liu C.C. In vivo conversion of γ-aminobutyric acid and 1,4-butanediol to γ-hydroxybutyric acid in rat brain. Biochem. Pharmacol. 38:1989;4375-4380.
19. Soudijn W., van Wijngaarden I., Ijzerman A.P. Allosteric modulation of G protein-coupled receptors. Curr. Opin. Drug Discov. Dev. 5:2002;749-755.
20. Van Sassenbroeck D.K., De Paepe P., Belpaire F.M., Boon P.A., Buylaert W.A. Tolerance to the hypnotic and electroencephalographic effect of gamma-hydroxybutyrate in the rat: pharmacokinetic and pharmacodynamic aspects. J. Pharm. Pharmacol. 55:2003;609-615.
21. Zvosec D.L., Smith S.W., McCutcheon J., Spillane J., Hall B.J., Peacock E.A. Adverse events, including death, associated with the use of 1,4 butanediol. N. Engl. J. Med. 344:2001;87-94.